Yazar "Vural, Filiz" seçeneğine göre listele
Listeleniyor 1 - 5 / 5
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Acute lymphoblastic leukemia in routine practice: A Turkish multicenter study(Turkish Society of Hematology, 2019) Çiftçiler, Rafiye; Sevindik, Ömür Gökmen; Tekgündüz, Ali İrfan Emre; Erkurt, Mehmet Ali; Vural, Filiz; Turgut, Burhan; Kaynar, Leylagül; Payzın, Bahriye; Doğu, Mehmet Hilmi; Karakuş, Volkan; Altuntaş, Fevzi; Büyükaşık, Yahya; Demirkan, FatihObjective: Significant developments occurred in the clinical management of acute lymphoblastic leukemia (ALL) in adults in recent decades. However, treatment results are still not satisfactory, especially in routine practice. The objective of this study was to evaluate the general clinical features, treatment details, and outcomes of a large group of patients followed in multiple centers in Turkey with a diagnosis of ALL. Materials and Methods: A retrospective analysis of the data of patients with ALL was made, the patients having been diagnosed and treated between January 2003 and June 2017 by different protocols in the hematology clinics of ten different centers. A total of 288 patients, aged between 17 and 76 years old, were included in the study. In this retrospective multicenter analysis of patients with ALL, classification of patients was performed based on treatment period, Philadelphia chromosome positivity, treatment regimen, and administration of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Results: The majority of cases were B-cell in origin, while 224 patients had B-ALL and 64 of the patients had T-ALL. Median follow-up duration for all patients was 18.2 months (range: 0.03-161 months). Philadelphia chromosome positivity was determined in 49 patients (21.9%), and 54 patients (18.8%) were receiving allo-HSCT. After induction chemotherapy, 219 patients (76.0%) achieved complete remission, 32 patients (11.2%) were evaluated as treatment refractory, and 37 patients (12.8%) were deceased. Median overall survival was 47.7 months (95% confidence interval: 36.1-59.2) and median disease-free survival was 23.4 months (95% confidence interval: 6.7-40.0) for all patients. Conclusion: Multicenter studies are extremely important for defining the specific clinical features of a particular disease. The results of this study will make a significant contribution to the literature as they reflect real-life data providing valuable information about the Turkish ALL patient profile.Öğe An interim analysis of the Turkish Myeloma Registry among patients who have received up to two lines of therapy(CIG Media Group, 2021) Sevindik, Ömür Gökmen; Özkurt, Zübeyde Nur; Boğa, Can; Kalayoğlu Beşışık, Sevgi; İpek, Yıldız; Gedük, Ayfer; Harmandalı, Aybüke; Salihoğlu, Ayşe; Haydaroğlu Şahin, Handan; Sönmez, Mehmet; Vural, Filiz; Akay, Olga Meltem; Kurt Yüksel, Meltem; Maral, Senem; Ekinci, Ömer; Kırkızlar, Hakkı Onur; Tekinalp, Atakan; Demir, Nazlı; Merter, Mustafa; Saydam, Güray; Alacacıoğlu, İnci; Yeğin, Zeynep Arzu; Kasar, Mutlu; Mastanzade, Metban; Özsan, Güner HayriBackground To investigate the demographics and treatment details of the myeloma patients who were diagnosed and followed up in Turkey and received up to two lines of therapy. Methods Patients who were recorded on the database of Turkish Myeloma Registry project were included in this study if they had only received one or two lines of therapy. Demographics, patient, and disease related parameters both at the time of diagnosis and at the follow up and treatment outcomes were presented.Öğe An interim analysis of the Turkish myeloma registry among the patients who have received up to two lines of therapy(American Society of Hematology, 2021) Sevindik, Ömür Gökmen; Özkurt, Zübeyde Nur; Boğa, Can; Kalayoğlu Beşışık, Sevgi; Yıldız, İpek; Gedük, Ayfer; Harmandali, Aybüke; Salihoğlu, Ayşe; Haydaroğlu Şahin, Handan; Sönmez, Mehmet; Vural, Filiz; Akay, Olga Meltem; Kurt Yüksel, Meltem; Maral, Senem; Ekinci, Ömer; Kırkızlar, Hakkı Onur; Tekinalp, Atakan; Demir, Nazlı; Merter, Mustafa; Saydam, Güray; Alacacıoğlu, İnci; Yeğin, Zeynep Arzu; Kaşar, Mutlu; Mastanzade, Metban; Özsan, Güner Hayri[Abstract Not Available]Öğe Current practice of autologous hematopoietic progenitor cell mobilization in adult patients with multiple myeloma and lymphoma: The results of a survey from Turkish hematology research and education group (ThREG)(Pergamon-Elsevier Science Ltd., 2017) Tekgündüz, Emre; Demirkan, Fatih; Vural, Filiz; Göker, Hakan; Özdoğu, Hakan; Kiki, İlhami; Aydoğdu, İsmet; Kaynar, Leylagül; Erkurt, Mehmet Ali; Çağırgan, Seçkin; Beşışık, Sevgi; Dağdaş, Simten; Koca, Ebru; Kadıköylü, Gürhan; Gündüz, Eren; Yılmaz, Mehmet; Beköz, Hüseyin; Ural, Ali Uğur; Baştürk, Abdulkadir; Arat, Mutlu; Albayrak, Murat; Öztürk, Erman; Akyol, Alev; Bolaman, Ali Zahit; Nevruz, Oral; Özkan, Hasan Atilla; Özgür, Gökhan; Altuntaş, FevziAutologous hematopoietic cell transplantation (AHCT) is an established treatment option for adult patients presenting with multiple myeloma (MM), Hodgkin lymphoma (HL) and various subtypes of non-Hodgkin lymphoma (NHL) in upfront and/or relapsed/refractory disease settings. Although there are recently published consensus guidelines addressing critical issues regarding autologous hematopoietic progenitor cell mobilization (HPCM), mobilization strategies of transplant centers show high variability in terms of routine practice. In order to understand the current institutional policies regarding HPCM in Turkey and to obtain the required basic data for preparation of a national positional statement on this issue, Turkish Hematology Research and Education Group (ThREG) conducted a web-based HPCM survey. The survey was designed to include multiple-choice questions regarding institutional practice of HPCM in adults presenting MM, HL, and NHL. The representatives of 27 adult HCT centers participated to the study. Here we report the results of this survey shedding light on the real world experience in Turkey in terms of autologous HPCM mobilization strategies in patients presenting with MM and lymphoma. (C) 2017 Elsevier Ltd. All rights reserved.Öğe Turkish acute lymphoblastic leukemia registry, retrospective phase data(The American Society of Hematology, 2019) Demirkan, Fatih; Çiftçiler, Rafiye; Sevindik, Ömür Gökmen; Tekgündüz, Emre; Erkurt, Mehmet Ali; Vural, Filiz; Turgut, Burhan; Kaynar, Leylagül; Payzin, Kadriye Bahriye; Doğu, Mehmet Hilmi; Karakuş, Volkan; Altuntaş, Fevzi; Büyükaşık, YahyaBackground and Aim: Significant developments have occurred in clinical management of acute lymphoblastic leukemia (ALL) in adults over recent decades. However, treatment results are still not satisfactory especially in routine practice. The aim of the study was to evaluate the general clinical features, treatment details and outcomes of a large group of patients followed up in multiple centers in Turkey with a diagnosis of ALL.
